MHY1485 ameliorates UV-induced skin cell damages via activating mTOR-Nrf2 signaling

  • Oncotarget. 2017 Feb 21;8(8):12775-12783. doi: 10.18632/oncotarget.14299.
Bo Yang  1 Qiu-Yun Xu  2 Chun-Yan Guo  2 Jin-Wen Huang  2 Shu-Mei Wang  2 Yong-Mei Li  1 Ying Tu  3 Li He  3 Zhi-Gang Bi  4 Chao Ji  2 Bo Cheng  2
Affiliations
  • 1. Department of Dermatology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • 2. Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • 3. Department of Dermatology, The First Affiliated Hospital of Kunming Medical University, Yunnan Provincial Institute of Dermatology, Kunming, China.
  • 4. Department of Dermatology, BenQ Medical Center, Nanjing Medical University, Nanjing, China.
Abstract

Ultra Violet (UV)-caused skin cell damage is a main cause of skin Cancer. Here, we studied the activity of MHY1485, a mTOR Activator, in UV-treated skin cells. In primary human skin keratinocytes, HaCaT keratinocytes and human skin fibroblasts, MHY1485 ameliorated UV-induced cell death and Apoptosis. mTOR activation is required for MHY1485-induced above cytoprotective actions. mTOR kinase inhibitors (OSI-027, AZD-8055 and AZD-2014) or mTOR shRNA knockdown almost abolished MHY1485-induced cytoprotection. Further, MHY1485 treatment in skin cells activated mTOR downstream NF-E2-related factor 2 (Nrf2) signaling, causing Nrf2 Ser-40 phosphorylation, stabilization/upregulation and nuclear translocation, as well as mRNA expression of Nrf2-dictated genes. Contrarily, Nrf2 knockdown or S40T mutation almost nullified MHY1485-induced cytoprotection. MHY1485 suppressed UV-induced Reactive Oxygen Species production and DNA single strand breaks in skin keratinocytes and fibroblasts. Together, we conclude that MHY1485 inhibits UV-induced skin cell damages via activating mTOR-Nrf2 signaling.

Keywords
MHY1485; Nrf2; mTOR; skin cell damage; ultra violet (UV).
Products